144 related articles for article (PubMed ID: 36796466)
21. Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity.
Rau R; Brown P
Hematol Oncol; 2009 Dec; 27(4):171-81. PubMed ID: 19569254
[TBL] [Abstract][Full Text] [Related]
22. Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia.
Andresen V; Erikstein BS; Mukherjee H; Sulen A; Popa M; Sørnes S; Reikvam H; Chan KP; Hovland R; McCormack E; Bruserud Ø; Myers AG; Gjertsen BT
Cell Death Dis; 2016 Dec; 7(12):e2497. PubMed ID: 27906185
[TBL] [Abstract][Full Text] [Related]
23. N6L pseudopeptide interferes with nucleophosmin protein-protein interactions and sensitizes leukemic cells to chemotherapy.
De Cola A; Franceschini M; Di Matteo A; Colotti G; Celani R; Clemente E; Ippoliti R; Cimini AM; Dhez AC; Vallée B; Raineri F; Cascone I; Destouches D; De Laurenzi V; Courty J; Federici L
Cancer Lett; 2018 Jan; 412():272-282. PubMed ID: 29111347
[TBL] [Abstract][Full Text] [Related]
24. A Curious Novel Combination of
Venanzi A; Rossi R; Martino G; Annibali O; Avvisati G; Mameli MG; Sportoletti P; Tiacci E; Falini B; Martelli MP
Genes (Basel); 2021 Sep; 12(9):. PubMed ID: 34573408
[No Abstract] [Full Text] [Related]
25. Small molecules enhancers of amyloid aggregation of C-terminal domain of Nucleophosmin 1 in acute myeloid leukemia.
Florio D; Roviello V; La Manna S; Napolitano F; Maria Malfitano A; Marasco D
Bioorg Chem; 2022 Oct; 127():106001. PubMed ID: 35803020
[TBL] [Abstract][Full Text] [Related]
26. Acute myeloid leukemia with mutated nucleophosmin (NPM1): any hope for a targeted therapy?
Falini B; Gionfriddo I; Cecchetti F; Ballanti S; Pettirossi V; Martelli MP
Blood Rev; 2011 Nov; 25(6):247-54. PubMed ID: 21724308
[TBL] [Abstract][Full Text] [Related]
27. Mutant NPM1 Maintains the Leukemic State through HOX Expression.
Brunetti L; Gundry MC; Sorcini D; Guzman AG; Huang YH; Ramabadran R; Gionfriddo I; Mezzasoma F; Milano F; Nabet B; Buckley DL; Kornblau SM; Lin CY; Sportoletti P; Martelli MP; Falini B; Goodell MA
Cancer Cell; 2018 Sep; 34(3):499-512.e9. PubMed ID: 30205049
[TBL] [Abstract][Full Text] [Related]
28. Mutant NPM1 maintains RASGRP3 protein stability via interaction with MID1 to promote acute myeloid leukemia cell proliferation and autophagy.
Wang Y; Pan C; Zhang X; Zhao A; Dong Y
J Leukoc Biol; 2023 May; 113(5):504-517. PubMed ID: 36826998
[TBL] [Abstract][Full Text] [Related]
29. INPP4B promotes cell survival via SGK3 activation in NPM1-mutated leukemia.
Jin H; Yang L; Wang L; Yang Z; Zhan Q; Tao Y; Zou Q; Tang Y; Xian J; Zhang S; Jing Y; Zhang L
J Exp Clin Cancer Res; 2018 Jan; 37(1):8. PubMed ID: 29343273
[TBL] [Abstract][Full Text] [Related]
30. Nucleophosmin gene mutations in acute myeloid leukemia.
Chen W; Rassidakis GZ; Medeiros LJ
Arch Pathol Lab Med; 2006 Nov; 130(11):1687-92. PubMed ID: 17076533
[TBL] [Abstract][Full Text] [Related]
31. Prognostic Impact of Concurrent DNMT3A, FLT3 and NPM1 Gene Mutations in Acute Myeloid Leukemia Patients.
Elrhman HAEA; El-Meligui YM; Elalawi SM
Clin Lymphoma Myeloma Leuk; 2021 Dec; 21(12):e960-e969. PubMed ID: 34376373
[TBL] [Abstract][Full Text] [Related]
32. Nucleophosmin Mutants Promote Adhesion, Migration and Invasion of Human Leukemia THP-1 Cells through MMPs Up-regulation via Ras/ERK MAPK Signaling.
Xian J; Shao H; Chen X; Zhang S; Quan J; Zou Q; Jin H; Zhang L
Int J Biol Sci; 2016; 12(2):144-55. PubMed ID: 26884713
[TBL] [Abstract][Full Text] [Related]
33. Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1.
Balusu R; Fiskus W; Rao R; Chong DG; Nalluri S; Mudunuru U; Ma H; Chen L; Venkannagari S; Ha K; Abhyankar S; Williams C; McGuirk J; Khoury HJ; Ustun C; Bhalla KN
Blood; 2011 Sep; 118(11):3096-106. PubMed ID: 21719597
[TBL] [Abstract][Full Text] [Related]
34. NPM1 ablation induces HSC aging and inflammation to develop myelodysplastic syndrome exacerbated by p53 loss.
Morganti C; Ito K; Yanase C; Verma A; Teruya-Feldstein J; Ito K
EMBO Rep; 2022 May; 23(5):e54262. PubMed ID: 35229971
[TBL] [Abstract][Full Text] [Related]
35. Structural consequences of nucleophosmin mutations in acute myeloid leukemia.
Grummitt CG; Townsley FM; Johnson CM; Warren AJ; Bycroft M
J Biol Chem; 2008 Aug; 283(34):23326-32. PubMed ID: 18511415
[TBL] [Abstract][Full Text] [Related]
36. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications.
Falini B; Bolli N; Liso A; Martelli MP; Mannucci R; Pileri S; Nicoletti I
Leukemia; 2009 Oct; 23(10):1731-43. PubMed ID: 19516275
[TBL] [Abstract][Full Text] [Related]
37. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
Paschka P; Schlenk RF; Gaidzik VI; Habdank M; Krönke J; Bullinger L; Späth D; Kayser S; Zucknick M; Götze K; Horst HA; Germing U; Döhner H; Döhner K
J Clin Oncol; 2010 Aug; 28(22):3636-43. PubMed ID: 20567020
[TBL] [Abstract][Full Text] [Related]
38. Acute myeloid leukemia with mutated nucleophosmin (NPM1): molecular, pathological, and clinical features.
Falini B
Cancer Treat Res; 2010; 145():149-68. PubMed ID: 20306250
[TBL] [Abstract][Full Text] [Related]
39. The human nucleophosmin 1 mutation A inhibits myeloid differentiation of leukemia cells by modulating miR-10b.
Zou Q; Tan S; Yang Z; Wang J; Xian J; Zhang S; Jin H; Yang L; Wang L; Zhang L
Oncotarget; 2016 Nov; 7(44):71477-71490. PubMed ID: 27669739
[TBL] [Abstract][Full Text] [Related]
40. FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics.
Rezaei N; Arandi N; Valibeigi B; Haghpanah S; Khansalar M; Ramzi M
Turk J Haematol; 2017 Dec; 34(4):300-306. PubMed ID: 28294102
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
